Academia Sinica/National Biotechnology Research Park

Academia Sinica
National Biotechnology Research Park (NBRP)
Biomedical Translation Research Center, BioTReC
Innovation and Incubation Division/BioHub Taiwan
Taiwan Biobank
Taiwan Mouse Clinic
National Core Facility for Biopharmaceuticals
Resident Companies of NBRP
Value-Added MedChem Innovation Center
Excelsior Biopharma Inc. / Excelsior Pharmatech Labs.
ALPS BIOTECH., LTD
Pharmaessentia Corp.

ALPS BIOTECH CO., LTD

Alps Biotech is a new drug research and development company dedicated to the study of natural products since 1999. Alps Biotech focuses on the development of biochemical research, new drug development, and healthy product development, as well as a variety of professional biotechnology services, such as protein separation, purification and identification technology.

An Fam Enterprise Co., Ltd.

Opentrons OT-2 Liquid Handling platform, Thermocycler Module, Magnetic Module
MEGAROBO T4 4-axis robot arm

Bora Pharmaceuticals Co Ltd

Bora Pharmaceutical is one of the premier pharmaceutical companies in Taiwan that covers the entire pharmaceutical supply chain from research and development all the way to sales and distribution. We provide pharmaceutical CDMO and CMO services for Taiwan domestic and global pharmaceutical companies around the world.
We are looking forward to become your best partner based in Asia to help connect your products to the world.

CDC Development India Pvt Ltd.

TIIP is meant to be the pioneer industrial park for the High-End Technology, Electronics, EV, and Bio-tech companies to set up their manufacturing and R&D arms in this most advanced city of India, Bangalore.
State of art and Well equipped and comprehensive infrastructure will give the business investors the home coming atmosphere to settle their units within the park and start their operation in fast track.

Century Biotech Development Corporation

To enhanceand promote a world class biotech industry cluster in Taipei area,Taipei City Government aggressively promoted "Taipei NanKang Biotech Park" to provide a state of the art industrial space to host the development of new drugs and advanced medical devices. It is meant to bring the discovery of research in neighboring Academia Sinica, Taiwan national institute to preclinical study and extend to clinical study and pilotproduction of new drugs. This park is equipped with incubation center to provide the space to host new startups and well planned infrastructure for well-built biotech companies to accommodate their requirements for laboratory, office and pilot production spaces.
With its outstanding location for transportation, next to Nangkang Station, Taipei NanKang Biotech Park will enrich the portfolio of Taipei hi-tech Industrial clusters and itself becomes one of the landmarks of Taipei East District Gateway Project.

Development Center for Biotechnolgoy

Development Center for Biotechnology (DCB) is founded in 1984 and has its mission to facilitate the ongoing growth and development of Taiwan's biotech industry. To this end, we strive to act as the industry's partner, coordinating resources among government, academia and private companies. DCB plays a key role in building and upgrading Taiwan's biomedical infrastructure, developing critical technologies and culturing Taiwan's professional workforce, and also contually fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
In both fields of small molecules and biologics, we may provide plenty of drug development services as well as new drug candidates for out-licensing, which are in the preclinical stage, and platforms which can be adopted in your design of drugs.
Info of said candidates for out-licensing, please refer to:
DCB：https://www.dcb.org.tw/
DCB Technology promotion：https://www.dcb.org.tw/posts/729
www.dcb.org.tw/pages/12
www.dcb.org.tw/technologies
https://www.dcb.org.tw/posts/729

EirGenix, Inc.

EirGenix has core capacity in R&D and manufacturing, producing biologics compliant with PIC/S GMP, and has 7 products undergoing development. EirGenix has two main business units:

1.Contract Development & Manufacturing Operation Unit:
EirGenix produces microbial and mammalian cell based biologics compliant with PIC/S GMP from cell line development to drug substance, and provides process development and quality control (QC) analysis for products.

Cell Line Development & Cell Banking Service:
Contract Development & Manufacturing Service:
Analytical Science & QC analysis Service:
Antibody Drug Conjugate (ADC) service: Partnering with Formosa Laboratories, Ltd.

2.Product Development & Operations Unit:
EirGenix currently has seven biologics undergoing development.

EG12014/EGI014 (Trastuzumab Biosimilar) treats HER2 gene variance cancer. It received approval from US FDA, Taiwan FDA, EMA...etc and began phase III clinical trial.
EG1206A (Pertuzumab Biosimilar) treats HER2 gene variance cancer.
EG13074 (New Formulation) treats HER2 gene variance cancer.
TSY0110(EG12043) (Antibody-Drug Conjugate) treats HER2 gene variance cancer.
EG12021 (Bevacizumab Biosimilar) inhibits cancer by anti-angiogenesis.
EG74032 (CRM197 Carrier Protein) can be used for vaccination.
EG62054 (Biosimilar)

Excelsior Pharmatech Labs.

待補

GlaxoSmithKline Far East B. V. Taiwan Branch

GSK is science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our goal is to be one of the world's most innovative, best performing and trusted healthcare companies. In this exhibition, we will be showcasing our innovations in healthcare and the work we do in Taiwan.